natgillin/translations-raw huggingface dataset:
Since the IL-18BP is eluted in a narrow peak (see in FIG. 3, 5 fractions of 3 ml each), the concentration factor increased by two-fold. 
Budući da do eluacije IL-18BP dolazi u uskom peak-u (vidi Sliku 3, 5 frakcija sa po 3 ml), faktor koncentriranja je porastao dva puta.
A self-adhesive transdermal device including the association of a support layer and a self-adhesive matrix layer and a detachable protective film, said self-adhesive matrix layer allowing the device to adhere to the skin for at least 12 hours and said self-adhesive matrix layer including: 
Samoljepljiva transdermalna naprava, naznačena time da obuhvaća kombinaciju podupirajućeg sloja i sloja samoljepljive matrice te zaštitnog filma koji se može odvojiti, a rečeni sloj samoljepljive matrice prema ukupnoj masi sloja samoljepljive matrice sadrži sljedeće:
According to another aspect of the above embodiment, a method is provided wherein the aqueous solution in step c) comprises at least 70% v/v methanol, such as at least 90% v/v methanol, such as at least 95% v/v methanol as a water miscible organic solvent. 
Postupak prema zahtjevu 9, naznačen time da organsko otapalo koje se miješa s vodom je metanol. Postupak prema zahtjevu 11, naznačen time da vodena otopina u koraku c) sadrži najmanje 70 % v/v metanola, odnosno najmanje 90 %v/v metanola, odnosno najmanje 95 % v/v metanola kao organskog otapala koje se miješa s vodom.
According to another alternative, assembled the volume filling device is adapted to be placed on the outside of the stomach wall with the outer surface of the volume filling device resting against the outside of the stomach wall, such that the volume of the food cavity is reduced in size by a volume substantially exceeding the volume of the volume filling device. 
usadljivi uređaj za rukovanje (90; 42; 54; 40; 217; 218; 452), namijenjen rukovanju uređajem za rastezanje kada je usađen, kako bi rastegnulo dio stijenke želuca, tako da se stvori osjećaj sitosti, naznačen time što je upravljivi uređaj za rastezanje prilagođen za stavljanje s vanjske strane stijenke želuca.
The solid pharmaceutical composition of clause 1, further comprising an adhesive agent. The solid pharmaceutical composition of clause 4, wherein the adhesive agent is selected from the group consisting of sucrose aluminum sulfate complex, chitosan and derivatives thereof, polyvinylpyrrolidone, methylcellulose, sodium carboxymethylcellulose, hydroxypropyl cellulose, cross-linked or uncross-linked polyacrylates, cross-linked polyacrylates, acidic cross-linked or uncross-linked polyacrylates, polyacrylic acid homopolymers or copolymers, aminoalkyl methacrylate copolymers, methacrylic acid/methylmethacrylate copolymer, alkylacrylate/alkylmethacrylate copolymers, ammoniomethacrylate copolymers, carbomer homopolymers or copolymers, hydrophilic polysaccharide gums, maltodextrins, cross-linked alignate gum gels, polycarboxylated vinyl polymers, pectins, xanthan gums, alginic acid, modified alginic acids, and combinations thereof. 
Tableta za oralno disperziranje sukladno bilo kojem od zahtjeva 1-3, koja nadalje sadrži adheziv, pri čemu je adheziv odabran iz skupine koju čine saharoza aluminijevog sulfata kompleksa, kitozana i njegovih derivata, polivinilpirolidona, metilceluloze, natrij karboksimetil celuloae, hidroksipropil celuloza, umreženih ili neumreženih poliakrilata, umreženi poliarilata, kiselih umreženi ili neumreženi poliakrilat, homopolimer ili kopolimer poliakrilne kiseline, aminoalkil metakrilatnih kopolimer, kopolimer metakrilne kiseline/metilmetakrilat, kopolimer alkilakrilat/alkitmetakrilat, amoniometakrilatnih kopolimer, karbomernih homopolimer ili kopolimer, hidrofilne polisaharidne gume, maltodekstrin, gelov umrežene alginatne gume, polikarboksilirane vinilne polimere, pektina, ksantanske gume, alginske kiseline, modificirane alginske kiseline ili njihovih kombinacija.
is selected from the group consisting of hydrogen, halo, oxo, and methyl; 
je odabran iz skupine koju sačinjavaju vodik i halo;
is selected from the group consisting of: 
ag odabrana iz skupine koju čine:
the DII4 antagonist and at least one additional therapeutic agent are for concurrent or sequential administration. 
(ii) antagonista DII4 i najmanje jedno dodatno terapeutsko sredstvo su namijenjeni za istovremenu ili uzastopnu primjenu.
The method of any one of claims 7 to 10, wherein the (±)-A9-tetrahydrocannabinol comprises at least 95% by weight, preferably at least 98% by weight and more preferably at least 99% by weight of trans-(-)-A9-tetrahydrocannabinol and trans-(+)-A9-tetrahydrocannabinol based on the total amount of cannabinoids. 
Postupak prema bilo kojem od zahtjeva 7 do 10, naznačen time da (±)-A9-tetrahidrokanabinol sadrži barem 95% težinski, poželjno barem 98% težinski i poželjnije barem 99% težinski trans-(-)-A9-tetrahidrokanabinola i trans-(+)-A9-tetrahidrokanabinola u odnosu na ukupnu količinu kanabinoida.
is an antibody or antigen binding fragment thereof that specifically binds a human folate receptor 1; is a linker; and 
Imunokonjugat formule (A) – (L) – (C), pri čemu je: protutijelo ili antigen vezujući fragment; je vezni dio; i
A method of treating a opioid toxicity or overdose in a subject in need thereof comprising administrating a first opioid receptor antagonist followed by a compound of Formula I: or a pharmaceutically acceptable salt, ester or prodrug thereof wherein; 
Spoj koji sadrži formulu: d Ket za uporabu u postupku liječenja opioidne toksičnosti ili predoziranja kod subjekta kojem je potrebno sadrži isporuku prvog antagonista receptora opioida nakon čega slijedi taj spoj.
In another embodiment, the infection is caused by an organism selected from the group consisting of K. pneumoniae, Salmonella, E. hirae, A. baumanii, M catarrhalis, H. influenzae, P. aeruginosa, E. faecium, E. coli, S. aureus, and E. faecalis. 
Spoj za uporabu prema patentnom zahtjevu 3, ili uporaba prema patentnom zahtjevu 4, naznačeno time da je zaraza uzrokovana bakterijom izabranom iz K. pneumoniae, Salmonella, E. hirae, A. baumanii, M. Catarrhalis, H. influenzae, P. aeruginosa, E. faecium, E. coli, S. aureus ili E. faecalis.
represents —H, or R0 is combined with R4 to represent C3-5 alkylene, and, 
R* predstavlja -H, ili je R" u kombinaciji s R* kada predstavljaju C3.s alkilen, te su
A rodent ES cell comprising an immunoglobulin light chain locus that comprises at an endogenous immunoglobulin light chain locus a single rearranged human immunoglobulin light chain variable region gene sequence operably linked to an immunoglobulin light chain constant region sequence and derived from a rearranged Yk1-39/JK or Vk3-20/JK sequence, and wherein the single rearranged human immunoglobulin light chain variable region gene sequence comprises the Yk1-39/JK gene sequence comprising a replacement of at least one non-histidine codon with a histidine codon designed to express a histidine at a position selected from 105, 106, 108, 111, and a combination thereof 
Embrionalna matična stanica glodavca koja sadrži lokus imunoglobulinskog lakog lanca koji sadrži na lokusu endogenog imunoglobulinskog lakog lanca jednu preuređenu gensku sekvencu varijabilne regije humanog imunoglobulinskog lakog lanca operativno povezanu sa sekvencom konstantne regije imunoglobulinskog lakog lanca 1 dobivenu iz preuređene VK1-39/Jx ili VK3-20/Jk sekvence, te naznačena time, što (1) jedna preuređena genska sekvenca varijabilne regije humanog imunoglobulinskog lakog lanca sadrži Vx139/JK gensku sekvencu koja se sastoji od zamjene najmanje jednog nehistidinskog kodona histidinskim kodonom dizajniranim da izražava histidin (a) na položaju odabranom iz 105, 106, 108, 111 1 njihove kombinacije;
An extract for use according to claim 5, 6 or 7, wherein the alcohol is selected from the group consisting of methanol, ethanol, propanol, isopropanol, butanol and mixtures thereof, the ketone is selected from the group consisting of acetone, methyl isobutyl ketone and mixtures thereof, the ester is selected from the group consisting of methyl acetate, ethyl acetate and mixtures thereof, the halogenated hydrocarbon is selected from the group consisting of chloroform, dichloromethane, ethylene dichloride and mixtures thereof, the ether is diethyl ether and the petroleum fraction is selected from the group consisting of hexane, petroleum ether, heptane and mixtures thereof. 
Ekstrakt za uporabu u skladu s patentnim zahtjevom 5, 6 ili 7, naznačen time, da je alkohol odabran iz skupine koju čine metanol, etanol, propanol, izopropanol, butanol i njihove smjese, keton je odabran iz skupine koju čine aceton, metil izobutil keton i njihove mješavine, ester je odabran iz skupine koju čine metil acetat, etil acetat 1 njihove smjese, halogenirani ugljikovodik je odabran iz skupine koju čine kloroform, diklorometan, etilen diklorida i njihovih smjesa, eter je dietil eter i naftna frakcija je odabrana iz skupine koja se sastoji od heksana, petroletera, heptana i njihovih smjese.
said second polypeptide chain comprises an amino (N-) terminus and a carboxy (C-) terminus and from N-terminus to C-terminus: 
navedeni drugi polipeptidni lanac sadrži amino terminus i karboksi terminus i od N-terminusa do C-terminusa:
Title compound was obtained as a white powder (m=9.923g) in a 68% yield. Melting point: 146°C 
Spoj iz naslova se dobije u obliku bijelog praha (m = 9,923 g) s prinosom od 68 %.
The roll of any of the preceding claims, wherein the V content in the steel composition is between 1.3 - 2.1 % V in terms of % per weight of total roll weight. 
Valjak prema prethodnim zahtjevima, pri čemu sadržaj V u sastavu čelika iznosi između 1,3-2,1 % V u postotnoj težini ukupne težine valjka.
The agent for the treatment and/or prophylaxis of a mood disorder, comprising the thiazole derivative or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein R2 is tetrahydropyranyl. 
[image] ili njegova farmaceutski prihvatljiva sol, te time, da se upotrebljava za liječenje i/ili profilaksu poremećaja raspoloženja odabranog od osnovne jake depresije, distimije, sindroma povezanog s depresijom, simptoma depresije na temelju fizičkog poremećaja i simptoma depresije izazvanog supstancom.
The pharmaceutical composition of claim 1, wherein said compound is 3-cyclopropyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-pyrazol-1-yl]-propionitrile; or a pharmaceutically acceptable salt thereof. 
Farmaceutski sastav koji sadrži spoj koji je 3-ciklopropil-3-[4-(7H-pirolo[2,3-d]pirimidin-4il)-pirazol-1-il]-propionitril; ili njegovu farmaceutski prihvatljivu sol; i farmaceutski prihvatljiv nosač; pri čemu je navedeni sastav pogodan za oralnu primjenu i za osiguravanje produženog oslobađanja navedenog spoja ili navedene soli.
The conjugate or pharmaceutical composition for use as described in claim 6 or 7, wherein said method of treating cancer involves intra-arterial, intranasal, intraperitoneal, intravenous, intramuscular, subcutaneous, transdermal, or per os administration. 
Konjugat ili pripravak za uporabu kako je opisano u bilo kojem zahtjevu od 15 do 22, naznačen time da navedeni postupak liječenja karcinoma uključuje intraarterijalno, = intranazalno, = intraperitonealno, intravenozno, intramuskularno, potkožno, transdermalno ili per os davanje.
The tube of claim 2, wherein a thickness of the first elongated electrode is larger in the discharge region than along the first and second longitudinal edge portions. 
Cijev u skladu s patentnim zahtjevom 1, naznačena time, da je debljina prve izdužene elektrode (203a) veća u području pražnjenja (205) nego duž prvog i drugog uzdužnog rubnog dijela.
The process of claim 18, further comprising one of more of the following steps: a step of formulating the therapeutic for injection; a step of administering the therapeutic to a patient; a step of adding a preservative; and a step of removing residual host cell nucleic acids. 
Postupak prema zahtjevu 1, naznačen time da nadalje sadrži jedan ili više sljedećih koraka: korak inaktivacije; korak miješanja tri soja virusa kako bi se napravilo trovalentno cjepivo; korak formuliranja cjepiva za injekciju; korak kombiniranja cjepiva s adjuvansom; korak mjerenja sadržaja HA; korak podešavanja sadržaja HA, npr.
If the reaction goes too long (beyond 2h), the product begins epimerizing at the C-7 position. 
Ako reakcija traje suviše dugo (preko 2 sata) produkt sc počinje cpimcrizirati na položaju
The method of embodiment 631, wherein the citrate, succinate or acetate compound is sodium citrate, sodium succinate or sodium acetate, respectively. 
(1) spoj citrata, sukcinata ili acetata je natrijum citrat, natrijum sukcinat ili natrijum acetat, respektivno; i/ili HR P20170755T
The elements of the extraction module are fixed to a main frame 26. 
Elementi modula za ekstrakciju su pričvršćeni na glavni okvir 26.
In European patent application no. 
Broj objave europske prijave patenata:
Compound of following general formula (I): in which: 
Spoj sljedeće opće formule (I):
A method according to claim 11 and/or claim 12, wherein the treatment comprises the degradation and/or modification of cellulose and/or hemicellulose and/or a pectic substance. 
Postupak prema zahtjevu 11 i/ili zahtjevu 12, naznačen time da obrada obuhvaća degradaciju i/ili modifikaciju celuloze i/ili hemiceluloze i/ili pektinske tvari.
The front walls 5 of the lid 2 are longer than its rear wall 4 and the side walls 6 of the lid 2 are oblique. 
Prednji zidovi 5 poklopca 2 su duži od njegovog stražnjeg zida 4 i bočni zidovi 6 poklopca 2 su kosi.
The antibody, functional protein or pharmaceutical composition for use according to claim 24, wherein the B-cell Non-Hodgkin's lymphomas is small lymphocytic lymphoma, lymphoplasmacytoid lymphoma, mantle cell lymphoma, follicular lymphoma, mucosa-associated lymphoid tissue lymphoma, diffuse large cell lymphoma, and Burkitt's lymphoma; precursor B-lymphoblastic leukemia; and B-cell chronic lymphocytic leukemia, and multiple myeloma. 
Protutijelo, funkcionalni protein ili farmaceutski sastav za uporabu prema zahtjevu 24, naznačen/o time, da non-Hodgkin limfomi B-stanice su sljedeći: mali limfocitni limfom, limfoplazmacitoidni limfom, limfom plaštenih stanica, folikularni limfom, limfom tkiva povezan s limfoidnom mukozom, limfom velikih difuznih stanica 1 Burkittov limfom; prethodnik B-limfoblastne leukemije; i kronična limfocitna leukemija B-stanica, i višestruki mijelom.
A compound according to any of Claims 1 to 7, or a pharmaceutically acceptable salt thereof, for use in the treatment of a psychiatric disorder selected from the group consisting of bipolar disorder, schizophrenia, and generalized anxiety disorder. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju psihijatrijskog poremećaja koji se bira iz skupine koju čine bipolarni poremećaj, shizofrenija, te generalizirani anksiozni poremećaj.
The compound of claim 1 having the structure (If): 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što ima strukturu (If):
X-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-Gly-Trp-Y-Asp-Phe-NH2, wherein Y stands for an amino acid replacing methionine and X stands for a chemical group attached to the peptide for the purpose of diagnostic and/or therapeutic intervention at CCK-2 receptor relevant diseases. 
X-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-Gly-Trp-Y -Asp-Phe-NH>, pri čemu Y predstavlja aminokiselinu koja zamjenjuje metionin, i X predstavlja kemijsku skupinu koja je priključena na peptid u svrhu dijagnostičke i/ili terapeutske intervencije kod odgovarajućih bolesti vezanih uz CCK2-receptor.
The control meter of at least one of the preceding claims 1 to 3, wherein the interrupter (11, 11a, 11b) and the mechanical means (6, 7, 8, 9, 10) is located substantially inside a sealed container with part of the locking bar mandrel and the retaining spanner being accessible though an opening in the sealed container; and the locking bar mandrel comprises a lid (9) covering the retaining spanner (8), the retaining spanner being accessible for release from the locking position only by breaking the lid. 
Nadzorno brojilo iz najmanje jednog od prethodnih patentnih zahtjeva 1 do 3, naznačeno time, da su prekidač (11, 1la, 11b) i mehanički sklopovi (6, 7, 8, 9, 10) pretežno postavljeni unutar zapečaćenog spremnika, pri čemu se dio držala šipke za zaključavanje i natezač mogu dohvatiti kroz otvor u zapečaćenom spremniku; i držalo šipke za zaključavanje sadrži poklopac (9) koji pokriva natezač (8), a natezač je dostupan za oslobađanje iz položaja za zaključavanje samo tako da se razbije poklopac.
Any of the above embodiments are also embodiments of formula IB with the proviso that R7 does not exist in compounds of general formula IB. 
Bilo koji od oblika koji su gore navedeni također predstavljaju oblike formule IB pod uvjetom da R/ ne postoji u spojevima opće formule IB.
This receiving member 20 comprises a frusto-conical skirt portion 21, see Figure 5, which supports the outer surface of the shell wall 16. 
Ovaj element za prihvaćanje 20 ima dio plašta koji ima oblik krnjeg stošca 21, vidi sliku 5, na koji plašt se oslanja vanjska površina stijenke ljuske 16.
A 2-theta value as indicated typically means that specific value ± 0.2. 
2-theta vrijednost kao što je navedena uobičajeno znači da je specifična vrijednost + 0,2.
The residue was triturated using pet-ether (30-40 °C) and the organic solution concentrated once more. 
Ostatak se triturira uporabom petrolej etera (30-40 "C) i organska otopina se još jednom koncentrira.
A therapeutically effective amount of an alpha adrenergic receptor agonist or a pharmaceutically acceptable salt thereof for use in treating purpura in a subject, wherein purpura is selected from solar purpura, actinic purpura, senile purpura, Bateman's purpura, laser-induced purpura, purpura caused by physical trauma, purpura caused by physical trauma to the skin, cutaneous vasculature, and/or surrounding tissues, purpura caused by a medical procedure, purpura caused by a surgical procedure, and combinations thereof. 
HR P20190214 T1 PATENTNI ZAHTJEVI Terapeutski učinkovita količina agonista alfa adrenergijskog receptora ili njegove farmaceutski prihvatljive soli za uporabu u liječenju purpure kod subjekta, naznačena time što je purpura odabrana od solarne purpure, aktinske purpure, senilne purpure, Batemanove purpure, laserski inducirane purpure, purpure uzrokovane fizičkom traumom, purpure uzrokovane fizičkom traumom kože, kožne vaskulature, i/ili okolnih tkiva, purpure uzrokovane medicinskim postupkom, purpure uzrokovane kirurškim zahvatom i njihovim kombinacijama.
The solution was then transferred to a separatory funnel and the organic partition was washed with water until the pH of the water wash was approximately 7, then was washed with brine. The organic partition was dried over sodium sulfate and then was evaporated to a solid of Formula 8. 
Otopina je tada bila prenesena u lijevak za odjeljivanje, a organski dio je bio ispiran vodom sve dok pH vode od ispiranja nije bio približno 7, tada je otopina bila isprana sa slanom vodom Organski dio je bio osušen iznad natrij sulfata i tada je bio isparen u krutu tvar formule 8.
As shown in Example 3, said method allows maintaining a protein productivity level with recycled supports comparable to the protein productivity level obtained with non-recycled supports. 
Kako je prikazano u Primjeru 3, spomenuti postupak omogućava održavanje razine proteinske produktivnosti s recikliranim potporama koja se može usporediti s onom koja se postiže kada se rabe potpore koje se ne recikliraju.
A container assembly (100) comprising: a container (102); and the cap (104) of at least one of the preceding claims coupled to the container (102). 
Sklop spremnika (100) naznačen time da sadrži: spremnik (102); 1 poklopac (104) prema barem jednom od prethodnih zahtjeva spojen na spremnik (102).
To this regard, the shafts are made in order to exhibit limited friction so as not to jam when sliding inside the guides, facilitating this sliding motion. 
S obzirom na to, cilindrična tijela su načinjena tako da imaju ograničeno trenje, tako da nema smetnji kada kližu unutar vodilica, 1 time se olakšava kretanje pomoću klizanja.
A compound of the following formula: wherein 
Tvar sljedeće formule:
The heat pump of claim 1 further comprising an environmental seal located where the periphery of the hot-side heat spreader mechanically contacts the wall of the SAS structure and where the periphery of the cold-side heat spreader mechanically contacts the wall of the SAS structure. 
Toplinska pumpa prema zahtjevu 1, naznačena time, da nadalje obuhvaća okolišnu brtvu smještenu tamo gdje rubni dio toplinskog raspršivača koji predaje toplinu, mehanički dotiče zid od SAS-konstrukcije i tamo gdje rubni dio toplinskog raspršivača koji preuzima toplinu, mehanički dotiče zid od SAS-konstrukcije.
context offset obtaining unit (2230) configured to obtain a context offset used in entropy decoding of the first critical value flag for a current significant coefficient based on the number of previous transformation coefficients having consecutive 1s included in a current subset when the current significant coefficient is not initially entropy-decoded in the current subset and the previous transformation coefficients having consecutive 1s are decoded before the current significant coefficient, according to a scan order of the current subset; and 
pribavljanje (2530) kontekstnog pomaka upotrebljavanog u entropijskom dekodiranju indikatora prve kritične vrijednosti na osnovi broja prethodnih koeficijenata transformacije sa slijedećom ls; te pribavljanje (2540) indeksa konteksta koji označava kontekst upotrebljavan u entropijskom dekodiranju indikatora prve kritične vrijednosti upotrebom indeksa skupa konteksta i kontekstnog pomaka,
The method according to claim 1, wherein the organic solvent is selected from the group consisting of C1-C10 alcohols, esters of C1-C10 alcohols with C1-C10 carboxylic acids, and mixtures thereof. The method according to claim 17, wherein the organic solvent comprises a C1-C6 alcohol and an ester of C1-C6 alcohol with a C2-C6 carboxylic acid. 
Pripravak za primjenu prema bilo kojem od prethodnih zahtjeva, naznačen time, što je organsko otapalo odabrano iz skupine koja se sastoji od Ci-Ci9 alkohola, estera C;-C19 alkohola s Ci-Cio karboksilnim kiselinama 1 njihovih smjesa, a poželjno se sastoji od C;-C$ alkohola i estera C,-Cg alkohola s C2-Cg karboksilnom kiselinom.
A white solid was obtained which was purified by chromatography on silica gel (ethyl acetate/hexane—gradient 95:5/80:20). 
Dobivena je bijela kruta tvar koja je pročišćena kromatografijom na silikagelu (etil acetat/heksan - gradijent 95:5/80:20).
from 2.3 to 30 mg/mL of the chloride hydrochloride salt of fosnetupitant; optionally from 5 to 50 µg/mL palonosetron hydrochloride based on the weight of the free base; sodium hydroxide 
do 30 mg/mL klorid hidrokloridne soli fosnetupitanta; izborno od 5 do 50 µg/mL palonosetron hidroklorida na osnovu težine slobodne baze; natrij hidroksid;
The pharmaceutical composition according to claim 1, comprising at least two peptides, wherein said peptides comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 10, or SEQ ID NO: 12 to SEQ ID NO: 23; provided that the composition comprises at least one peptide comprising SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 12 or SEQ ID NO: 13 or a salt thereof further comprising mannitol and Tween® 80, wherein the ratio by weight of peptides to mannitol to Tween® 80 is in the range including and between 1:2:1.5 to 1:8:2.2. 
Farmaceutski sastav prema zahtjevu 1, koji se sastoji od najmanje dva peptida, gdje spomenuti peptidi sadrže slijed aminokiselina odabranih iz skupina koje se sastoje od ID br. baz.: 1 do ID br. baz.: 10, ili ID br. baz.: 12 do ID br. baz.: 23; pod uvjetom da sastav sadrži najmanje jedan peptid koji uključuje ID br. baz.:1, ID br. baz.: 2, ID br. baz.: 12 ili ID br. baz.: 13 ili njihove soli koje dalje uključuju manitol i Tween®80 gdje je omjer prema težini peptida prema manitolu prema Tween® 80 u rasponu uključujući i između 1:2:1.5 do 1:8:2.2.
A compound according to Formula I: wherein 
Spoj prema Formuli I: